{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:33:43Z","timestamp":1786991623118,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jcf.2023.07.001","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:54:56Z","timestamp":1689263696000},"page":"1027-1035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Tatiana","family":"Yuzyuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Zuromski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"De Biase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Meihls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6317-6845","authenticated-orcid":false,"given":"Fadi","family":"Asfour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.07.001_bib0001","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis: a review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr Clin Pract"},{"key":"10.1016\/j.jcf.2023.07.001_bib0002","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jcf.2023.07.001_bib0003","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jcf.2018.03.011","article-title":"Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis","volume":"17","author":"Sutherland","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/nu12051505","article-title":"Cardio-metabolic effects of high-fat diets and their underlying mechanisms-a narrative review","volume":"12","author":"Wali","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jcf.2023.07.001_bib0005","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"Cftr modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0006","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with Cystic Fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0007","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s44161-022-00030-y","article-title":"Identifying and preventing cardiovascular disease in patients with cystic fibrosis","volume":"1","author":"Saunders","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"10.1016\/j.jcf.2023.07.001_bib0008","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1079\/BJN19940199","article-title":"Plasma lipid concentrations in children with cystic fibrosis: the value of a high-fat diet and pancreatic supplementation","volume":"71","author":"Burdge","year":"1994","journal-title":"Br J Nutr"},{"key":"10.1016\/j.jcf.2023.07.001_bib0009","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/ajcn\/75.6.1005","article-title":"Abnormal lipid concentrations in cystic fibrosis","volume":"75","author":"Figueroa","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jcf.2023.07.001_bib0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcf.2009.09.002","article-title":"Prevalence of dyslipidemia in adults with cystic fibrosis","volume":"9","author":"Rhodes","year":"2010","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0011","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1440-1843.2010.01771.x","article-title":"Metabolic abnormalities in adults with cystic fibrosis","volume":"15","author":"Georgiopoulou","year":"2010","journal-title":"Respirol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0012","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4103\/2230-8210.98016","article-title":"Dyslipidemia in racially admixtured children with cystic fibrosis","volume":"16","author":"Alves","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.jcf.2023.07.001_bib0013","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jcf.2017.02.010","article-title":"Dietary intake and lipid profile in children and adolescents with cystic fibrosis","volume":"16","author":"Woestenenk","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0014","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jcf.2019.04.001","article-title":"Cystic fibrosis dyslipidaemia: a cross-sectional study","volume":"18","author":"Nowak","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jcf.2020.04.004","article-title":"Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis","volume":"19","author":"Colomba","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11236900","article-title":"Cystic fibrosis patients with F508del\/minimal function genotype: laboratory and nutritional evaluations after one year of elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"11","author":"Carnovale","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcf.2023.07.001_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2023.07.001_bib0018","doi-asserted-by":"crossref","first-page":"8138","DOI":"10.1038\/s41598-020-65100-2","article-title":"Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: the genes study","volume":"10","author":"Duparc","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2023.07.001_bib0019","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacl.2017.05.011","article-title":"Lipoprotein particle number and size predict vascular structure and function better than traditional lipids in adolescents and young adults","volume":"11","author":"Urbina","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2004.04.022","article-title":"Hepatic production of VLDL1 but not VLDL2 is related to insulin resistance in normoglycaemic middle-aged subjects","volume":"176","author":"Gill","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcf.2023.07.001_bib0021","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2015.07.040","article-title":"Lipoprotein particle subclass profiles among metabolically healthy and unhealthy obese and non-obese adults: does size matter?","volume":"242","author":"Phillips","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jcf.2023.07.001_bib0022","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jcf.2023.07.001_bib0023","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.jcf.2023.07.001_bib0024","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of nutrition and dietetics: 2020 cystic fibrosis evidence analysis center evidence-based nutrition practice guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jcf.2023.07.001_bib0025","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00082-2019","article-title":"Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles","volume":"5","author":"Taylor-Cousar","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2023.07.001_bib0026","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jcf.2023.07.001_bib0027","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/gut.52.8.1159","article-title":"Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas","volume":"52","author":"Ahmed","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.jcf.2023.07.001_bib0028","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0002-8223(94)90095-7","article-title":"Lipid levels in adults with cystic fibrosis","volume":"94","author":"Slesinski","year":"1994","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.jcf.2023.07.001_bib0029","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.healun.2010.08.024","article-title":"Impact of lung transplantation on serum lipids in adults with cystic fibrosis","volume":"30","author":"Nash","year":"2011","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.jcf.2023.07.001_bib0030","doi-asserted-by":"crossref","first-page":"L476","DOI":"10.1152\/ajplung.00262.2006","article-title":"Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis","volume":"292","author":"White","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245302","article-title":"Impaired cholesterol metabolism in the mouse model of cystic fibrosis. a preliminary study","volume":"16","author":"Amato","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jcf.2023.07.001_bib0032","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (arrival): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2023.07.001_bib0033","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a gut check: pancreatic sufficiency resulting from CFTR modulator use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0034","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after Ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2023.07.001_bib0035","doi-asserted-by":"crossref","first-page":"17066","DOI":"10.1038\/s41598-018-35151-7","article-title":"Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2023.07.001_bib0036","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/s42255-021-00470-z","article-title":"Metabolic messengers: tumour necrosis factor","volume":"3","author":"Sethi","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.jcf.2023.07.001_bib0037","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1203\/00006450-199308000-00011","article-title":"Circulating tumor necrosis factor-alpha levels and lipid abnormalities in patients with cystic fibrosis","volume":"34","author":"Levy","year":"1993","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jcf.2023.07.001_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.765749","article-title":"Improvements in high-density lipoprotein quantity and quality contribute to the cardiovascular benefits by anti-tumor necrosis factor therapies in rheumatoid arthritis: a systemic review and meta-analysis","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jcf.2023.07.001_bib0039","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.619442","article-title":"CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in cf bronchial epithelial cells","volume":"12","author":"Veltman","year":"2021","journal-title":"Front Physiol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323008317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:08:52Z","timestamp":1762031332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323008317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1569199323008317"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.07.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of lipid and lipoprotein profiles in children and adolescents with cystic fibrosis on CFTR modulator therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}